HbA1c Variability in Type II Diabetes

Launched by WEILL CORNELL MEDICAL COLLEGE IN QATAR · Aug 20, 2016

Keywords

ClinConnect Summary

This clinical trial is studying how changes in blood sugar levels, specifically the HbA1c measurement, might affect the risk of complications in people with Type 2 diabetes. Researchers want to see if treating patients to different blood sugar targets leads to different levels of HbA1c variability and how this relates to markers of stress and inflammation in the body. The trial will also look at small nerve fibers and heart function to understand better how these factors impact diabetes complications.

To participate, you need to be a Qatari adult aged 18 to 65 with Type 2 diabetes, currently taking medication, and have an HbA1c level between 7.5% and 9.0%. The study will involve about 20 visits over 2.5 years, where you will have routine tests, fill out questionnaires, and undergo specific tests to measure your nerve function and heart health. It's important to note that certain health conditions, like anemia or severe kidney problems, might prevent someone from participating. This trial is currently active but not recruiting new participants.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Qatari subjects only with type 2 diabetes taking any medication.
• • HbA1c 7.5-9.0%.
• • Body mass index 26-36.
• • Age 18 - 65 years of age.
• • Recruitment of a gender balance reflecting the local eligible diabetes patients until 150 are recruited.
• Exclusion Criteria:
• • Patients with anemia or other conditions known to affect the validity of HbA1c measurement e.g. a haemoglobinopathy known to affect the Hamad HbA1c method or renal failure (CKD Stage 5)
• • Patients with concurrent illness
• • Patients on medication leading to insulin resistance e.g. corticosteroids
• • Pregnancy
• • Active retinopathy
• • Any clinical exclusion for optimal diabetes control
• • Hypoglycemic unawareness